Back to Search
ADAM FALCONE, M.D.
M.D.
Interventional Cardiology Physician
NPI: 1558534958IndividualAccepts Medicare
Specialties, Licenses & Credentials
Interventional Cardiology PhysicianPrimary
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
N8781(TX)
Cardiovascular Disease Physician
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
N8781(TX)
Education
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Class of 2008
Research & Publications (20)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
PMID 19603018·Br J Cancer·2009
8-other
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
PMID 19663667·Pharmacogenomics·2009
5-case
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.
PMID 19534585·Expert Opin Biol Ther·2009
8-other
Chemotherapy and immunotherapy in metastatic colorectal cancer.
PMID 19445032·N Engl J Med·2009
8-other
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
PMID 19436300·Br J Cancer·2009
3-trial
Do we need biopsies of metastases for colorectal cancer patients?
PMID 19584870·Br J Cancer·2009
8-other
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
PMID 19622584·Clin Cancer Res·2009
3-trial
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
PMID 19329221·Lung Cancer·2009
3-trial
Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.
PMID 19289373·Clin Lung Cancer·2009
3-trial
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
PMID 19264832·Ann Oncol·2009
8-other
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
PMID 19259089·Br J Cancer·2009
8-other
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
PMID 19247029·Ann Surg·2009
8-other
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis.
PMID 19208600·J Rheumatol·2009
8-other
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.
PMID 19104506·Pharmacogenomics J·2009
8-other
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
PMID 19406725·Clin Lymphoma Myeloma·2009
3-trial
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
PMID 19398573·J Clin Oncol·2009
4-observational
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts.
PMID 19018865·Eur J Haematol·2009
8-other
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
PMID 19006547·Br J Clin Pharmacol·2009
8-other
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population.
PMID 18830612·Int J Colorectal Dis·2009
8-other
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
PMID 18839174·Cancer Chemother Pharmacol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7125 NEW SANGER AVE STE A
WACO, TX 76712 - Phone
- (254) 399-5400
Quick Facts
- NPI
- 1558534958
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 18
- Publications
- 20
Are you this provider?
Claim Your Profile